PMC6951398_01
Treatment procedure after post-operative relapse. PFS, progression-free survival; H, trastuzumab; DP, docetaxel/cisplatin; X, xeloda (capecitabine); EOX, epirubicin/oxaliplatin/xeloda; PR, partial response; PD, progressive disease; mo, months.
fonc-09-01453-g0001.jpg
PMC6951398_01_fonc-09-01453-g0001.jpg
F1
Figures 1-3 illustrate the entire treatment procedure and corresponding changes in the lesions on computed tomography (CT) scan and changes in CA19-9 levels.
Chest and abdominal computed tomography (CT) scans. (A) CT (2016-05) demonstrates multiple liver and lung metastases before first-line chemotherapy (DP: docetaxel and cisplatin) combined with trastuzumab (H). (B) Liver and lung metastases are reduced in size after second-line chemotherapy (EOX: epirubicin, oxaliplatin, and capecitabine) combined with trastuzumab. (C) CT (2017-11) demonstrates progressive disease (PD) in the lung and liver metastases when chemotherapy combined with trastuzumab failed. (D) CT (2017-12) reveals that a cavity is formed inside the pulmonary metastatic lesions, and the size of the liver metastases are reduced than before, after using fourth-line therapy (apatinib) for 1 month. (E) Lung and liver metastases are stable during apatinib treatment until 2018-07, when all the lesions progressed significantly. (F) After 4 weeks of oral lapatinib and apatinib treatment as fifth-line therapy, CT (2018-08) scans suggest new intrapulmonary nodules and intrahepatic metastases. (G) CT scans reveal hyper-progressive disease (HPD) and that the lesions are increased and enlarged significantly after treatment with nivolumab plus apatinib for 4 weeks. (H) CT scans (2018-12) show partial response (PR) in the hepatic and pulmonary metastatic lesions after using pyrotinib plus capecitabine for 1 month.
fonc-09-01453-g0002.jpg
PMC6951398_01_fonc-09-01453-g0002.jpg
F2
Figures 1-3 illustrate the entire treatment procedure and corresponding changes in the lesions on computed tomography (CT) scan and changes in CA19-9 levels.
Change in cancer antigen 19-9 (CA19-9) (U/ml) levels during entire treatment.
fonc-09-01453-g0003.jpg
PMC6951398_01_fonc-09-01453-g0003.jpg
F3
Figures 1-3 illustrate the entire treatment procedure and corresponding changes in the lesions on computed tomography (CT) scan and changes in CA19-9 levels.